EGFR and neoplasm: In the case of anti-EGF-R antibodies, besides being the only way to segregate the study of the functional consequences of affinity differences from the influence of recognition of different epitopes on the same target, keeping the uniqueness of nimotuzumab epitope is relevant in light of the growing number of mutations that are emerging upon anti-EGF-R treatments and mediate epitope loss and tumor resistance to therapy17–21,50.